{"id":295305,"date":"2024-03-12T00:00:00","date_gmt":"2024-03-12T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoop0001-2024-biopharma-dry-and-wet-age-related-macular-degeneration-current-treatment-treatment\/"},"modified":"2026-03-31T10:30:42","modified_gmt":"2026-03-31T10:30:42","slug":"algoop0001-2024-biopharma-dry-and-wet-age-related-macular-degeneration-current-treatment-treatment-algorithms-claims-data","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algoop0001-2024-biopharma-dry-and-wet-age-related-macular-degeneration-current-treatment-treatment-algorithms-claims-data\/","title":{"rendered":"Dry and Wet Age-Related Macular Degeneration &#8211; Current Treatment &#8211; Treatment Algorithms: Claims Data Analysis &#8211; Dry and Wet Age-Related Macular Degeneration (US)"},"content":{"rendered":"<p>The treatment of wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr> in the United States has been mainly dominated by three anti-<abbr data-abbreviation-entity=\"4987\" title=\"vascular endothelial growth factor\">VEGF<\/abbr> therapies: Roche \/ Genentech\u2019s off-label Avastin, Roche \/ Genentech\u2019s Lucentis, and Regeneron\u2019s Eylea. The market is becoming increasingly fragmented; newer entrants Roche\u2019s Vabysmo and Regeneron\u2019s Eylea <span class=\"abbreviation-guard\">HD<\/span> are being increasingly incorporated into the treatment algorithm of wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr> patients, while competition from biosimilars grows. Using national, longitudinal, patient-level U.S. claims data, this report examines recent trends in the management of wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr> both among newly diagnosed patients and among patients filling a prescription for a key therapy.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What patient shares do key therapies and brands garner by line of therapy in newly diagnosed wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr> patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed wet <abbr data-abbreviation-entity=\"4729\" title=\"age-related macular degeneration\">AMD<\/abbr> patients?<\/li>\n<li>How have Vabysmo and Eylea <span class=\"abbreviation-guard\">HD<\/span> been integrated into the treatment algorithm, and what are their sources of business?<\/li>\n<li>What percentage of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?<\/li>\n<li>What percentage of wet <abbr title=\"age-related macular degeneration\">AMD<\/abbr> patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies:<\/strong> Roche \/ Genentech, Regeneron, Novartis, Biogen, Samsung Bioepis<\/p>\n<p><strong>Key drugs:<\/strong> Avastin, Eylea, Lucentis, Beovu, Mvasi, Zirabev, Vabysmo, Susvimo, Byooviz, Cimerli<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.<\/p>\n<p><strong>Key feature<\/strong><\/p>\n<p><span class=\"TextRun SCXP60924648 BCX0\" data-contrast=\"none\" data-scheme-color=\"@000000,1,\" data-usefontface=\"true\" lang=\"EN-US\" xml:lang=\"EN-US\"><span class=\"NormalTextRun SCXP60924648 BCX0\" style=\"margin: 0px; padding: 0px; user-select: text; -webkit-user-drag: none; -webkit-tap-highlight-color: transparent; touch-action: pan-x pan-y; vertical-align: 0.37px; line-height: 0px; position: relative; text-decoration: none;\">Dashboard featuring<span>\u00a0<\/span><\/span><\/span>interactive visuals, easy navigation, and expanded analyses<\/p>\n","protected":false},"template":"","class_list":["post-295305","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-age-related-macular-degeneration","biopharma-therapy-areas-ophthalmology","biopharma-product-current-treatment","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295305","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295305\/revisions"}],"predecessor-version":[{"id":575981,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295305\/revisions\/575981"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}